EGFR protein: Structural basis of exon 20 mutations in the kinase domain and targeted therapeutic strategies

Author: Senior Product Manager of UA Views：10

This article focuses on the molecular structure of the epidermal growth factor receptor (EGFR) protein and the clinical significance of exon 20 mutations, systematically elaborating on the structural organization of the EGFR kinase domain and the conformational change mechanisms underlying exon 20 mutations, analyzing the essential differences in structure-function relationships between exon 20 insertion mutations and point mutations, and exploring the sensitivity patterns of different mutation types to various targeted drugs as well as the corresponding therapeutic strategies.

Recent Advances
Product Information

Recent Advances

EGFR Protein: Structural Basis of Exon 20 Mutations in the Kinase Domain and Targeted Therapeutic Strategies

Summary: This article focuses on the molecular structure of the epidermal growth factor receptor (EGFR) protein and the clinical significance of exon 20 mutations, systematically elaborating the structural organization of the EGFR kinase domain and the conformational change mechanisms of exon 20 mutations, analyzing the essential differences in structure-function relationships between exon 20 insertion mutations and point mutations, and discussing the sensitivity patterns of different mutation types to various targeted drugs and the corresponding therapeutic strategies.

I. Structural Organization of the EGFR Protein and Localization of the Kinase Domain.

The EGFR protein is encoded by 28 exons on chromosome 7, and its kinase domain is encoded by exons 18 to 24, consisting of a smaller N-terminal lobe and a larger C-terminal lobe, with the kinase active site located in the cleft between the two lobes. From the perspective of protein structure, EGFR contains, in its primary sequence, a ligand-binding extracellular region, a single transmembrane region, a kinase region, and a flexible C-terminal fragment. This structural layout determines how EGFR functions: the extracellular region receives ligand signals, the transmembrane region transmits conformational changes, and the kinase region initiates downstream signaling cascades by catalyzing the transfer of the phosphate group from ATP.

The nucleotides encoded by EGFR exon 20 are translated into amino acids 762 to 823 of the kinase domain, with amino acid 762 located at the N-terminus and amino acid 823 at the C-terminus; this segment includes part of the C-helix (residues 762 to 766), which plays an important role in kinase activation. Therefore, exon 20 is not a homogeneous structural unit but rather a heterogeneous segment spanning key regions of kinase activation, which also explains why different mutations within this region produce distinctly different functional consequences.

II. Structural Mechanisms and Diversity of Exon 20 Insertion Mutations.

Most exon 20 insertion mutations cause changes in the kinase domain that occur after the C-helix within the N-terminus, while a small portion are located within the C-helix, and they can lead to ligand-independent activation of the EGFR pathway. From a structural mechanism perspective, the C-helix undergoes conformational displacement during kinase activation, which is a key step in the transition of the kinase from the inactive to the active state; insertion mutations stabilize the active conformation by altering the length or amino acid composition of the loop region after the C-helix, enabling the kinase to maintain activity without ligand stimulation.

EGFR exon 20 in-frame duplication/insertion mutations account for approximately 4% of all EGFR mutations, making them the most common EGFR mutation type after exon 19 deletions and L858R, and they occur predominantly in Asian, female, non-smoking, and adenocarcinoma populations. More than 90% of exon 20 insertion mutations are located between S768 and V774, after the C-helix of the EGFR kinase region, while a small portion (about 4%) of insertions are located within the C-helix (G762 to M766). Unlike exon 19 deletions/insertions, exon 20 insertions exhibit diversity in insertion site, sequence, and length; the most common mutation type is D770_N771insSVD, followed by V769_D770insASV, and at least 120 other types have been reported in the literature to date. This triple diversity of site, sequence, and length is the structural root cause of why exon 20 insertion mutations are difficult to cover with a single drug.

III. Structural Differences Determine Drug Sensitivity: Molecular Basis of Sensitive and Resistant Mutations.

Classic exon 19 deletions and the L858R mutation cause conformational changes in the kinase region, destabilizing the inactive state of EGFR and shifting it toward the active state. Among exon 20 insertion mutations, the sensitive mutation A763_Y764insFQEA is a special type: the inserted FQEA shifts the C-helix toward the N-terminus, altering the length of the β3-αC loop and leading to an I759A substitution, and the β3-αC loop is the classic location of exon 19 deletion mutations; the I759A change is adjacent to the L858R and L861Q mutations. Thus, compared with other exon 20 insertion mutations, A763_Y764insFQEA is structurally more similar to L858R and exon 19 deletions, which also explains the structural basis for the certain sensitivity of this mutation type to first-generation targeted drugs.

In contrast, resistant types such as D770_N771insNPG have been shown in enzyme kinetic studies to have binding modes and apparent affinities similar to wild-type EGFR; this mutation activates EGFR without significantly reducing its affinity for ATP or increasing its affinity for EGFR tyrosine kinase inhibitors. Its three-dimensional crystal structure reveals that the mutation does not alter the ATP-binding pocket but rather that residues formed at the end of the C-helix activate the enzyme conformation. Structurally, exon 20 insertion mutants have affinity for first-generation drugs similar to that of wild-type, which may be the structural reason why patients carrying this mutation are insensitive to first- and second-generation targeted drugs.

IV. Types and Sensitivity Profiles of Exon 20 Point Mutations.

Unlike exon 20 insertion mutations, exon 20 point mutations do not structurally alter the conformational framework near the C-helix, and their drug sensitivity mainly depends on the relative relationship between the mutation site and the drug-binding pocket. T790M is the most representative point mutation: during treatment with first- and second-generation targeted drugs, resistance and tumor relapse inevitably occur at approximately 6 to 12 months, with 50% of acquired resistance associated with the T790M mutation; second-generation irreversible drugs have a response rate of less than 10% in patients with the T790M mutation and cannot overcome the first-generation drug resistance it causes. Third-generation drugs mainly target patients who develop secondary T790M resistance mutations after targeted therapy, and their selective action on the T790M mutation results in weaker inhibition of wild-type EGFR.

The S768I point mutation occurs in approximately 1.5% to 3% of patients with EGFR mutations and often co-occurs with exon 19 deletions, G719X, E709X, L861X, and other site mutations. Studies have confirmed that the S768I point mutation is moderately sensitive to first-generation drugs, but the sensitivity is lower than that of classic exon 19 deletions and the L858R mutation; compared with first-generation drugs, second-generation drugs have a more advantageous efficacy in S768I patients. The C797S/G mutation occurs 6 to 17 months after the T790M resistance mutation and is an acquired resistance mutation to third-generation drugs; it exists in cis/trans relationships with the T790M mutant allele, which is significantly correlated with the efficacy of targeted drugs: patients with T790M/C797S in trans are resistant to third-generation drugs but sensitive to combined first- and third-generation therapy, whereas patients with the cis mutation are insensitive to both monotherapy and combination therapy. The Q787Q mutation has been reported as a rare exon 20 point mutation sensitive to first-generation drugs.

V. Conclusion.

The EGFR protein, with its kinase domain encoded by exons 18 to 24, the amino acid segment corresponding to exon 20 at positions 762 to 823, and the key role of the C-helix within it in kinase activation, constitutes the structural basis for understanding the functional consequences of exon 20 mutations. In basic research and targeted drug development related to the EGFR protein, high-quality recombinant EGFR protein is a core tool for dissecting conformational changes in the kinase domain, evaluating the sensitivity of different mutation types to drugs, and conducting species cross-reactivity studies. To meet the needs of EGFR protein functional research and targeted drug development, Ulab provides EGFR His Tag Protein, Rhesus macaque. This product is suitable for applications such as binding activity analysis of EGFR protein with targeted drugs, studies on the conformation and activity of EGFR kinase domain mutants, in vitro evaluation of drug sensitivity of different mutation types, and species cross-reactivity analysis in preclinical toxicological evaluation.

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Nanjing Univ is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UNIV Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Last The Next